Adaptive, behavioral, and cognitive outcomes in individuals with fragile X syndrome with varying autism severity
Ramkumar Aishworiya,Ye Eun Tak,Matthew Dominic Ponzini,Hazel Maridith Barlahan Biag,Maria Jimena Salcedo-Arellano,Kyoungmi Kim,Flora Tassone,Andrea Schneider,Angela John Thurman,Leonard Abbeduto,David Hessl,Jamie Leah Randol,Francois V Bolduc,Sarah Lippe,Paul Hagerman,Randi Hagerman
DOI: https://doi.org/10.1002/jdn.10299
Abstract:This study aimed to determine the association between severity of autism spectrum disorder (ASD) and cognitive, behavioral, and molecular measures in individuals with fragile X syndrome (FXS). Study inclusion criteria included individuals with FXS and (1) age 6-40 years, (2) full-scale IQ < 84, and (3) language ≥3-word phrases. ASD symptom severity was determined by Autism Diagnostic Observation Schedule-2 (ADOS-2). Other measures identified non-verbal IQ, adaptive skills, and aberrant behaviors. Molecular measures included blood FMR1 and CYFIP1 mRNA levels, FMRP and MMP9 levels. Analysis of variance (ANOVA) and Spearman's correlations were used to compare ASD severity groups. Data from 54 individuals was included with no/mild (N = 7), moderate (N = 18), and severe (N = 29) ASD. Individuals with high ASD severity had lower adaptive behavior scores (47.48 ± 17.49) than the no/mild group (69.00 ± 20.45, p = 0.0366); they also had more challenging behaviors, lethargy, and stereotypic behaviors. CYFIP1 mRNA expression levels positively correlated with the ADOS-2 comparison score(r2 = 0.33, p = 0.0349), with no significant correlations with other molecular markers. In conclusion, autism symptom severity is associated with more adverse cognitive and adaptive skills and specific behaviors in FXS, whereas CYFIP1 mRNA expression levels may be a potential biomarker for severity of ASD in FXS.